Jerome B Zeldis sold $1.2M of PTCT
director at PTC THERAPEUTICS, INC.. 24,000 shares at an average of $51.50, traded Dec 2, 2024, filed Dec 4, 2024.
Score components
- +15RoleDirector
- +25Trade size$1.2M at market
- +20Share of holdings soldSold 91% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-028287, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 2, 2024 | MOption exercise Common Stock10b5-1 | +12,000 | $51.00 | $612k | 26,500 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock10b5-1 | -8,813 | $51.44 | $453k | 17,687 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock10b5-1 | -3,187 | $52.42 | $167k | 14,500 | Dec 4, 2024 |
| Dec 2, 2024 | MOption exercise Common Stock10b5-1 | +12,000 | $30.86 | $370k | 26,500 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock10b5-1 | -5,699 | $50.52 | $288k | 20,801 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock10b5-1 | -2,634 | $51.43 | $135k | 18,167 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock10b5-1 | -3,667 | $52.39 | $192k | 14,500 | Dec 4, 2024 |
| Dec 2, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,000 | $0.00 | $0 | 0 | Dec 4, 2024 |
| Dec 2, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,000 | $0.00 | $0 | 0 | Dec 4, 2024 |
Related signals
Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $158k 2,500 shares | -0% | |
| 6Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $133k 2,073 shares | -2% | |
| 27Weak | PTC THERAPEUTICS, INC. | Glenn Steele Jr Md Phd director | $782k 12,000 shares | -35% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.3M 20,000 shares | -2% | |
| 20Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.4M 20,000 shares | -1% | |
| 23Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $2.9M 35,572 shares | -35% | |
| 33Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $6.0M 71,928 shares | -70% | |
| 0Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $214k 2,812 shares | -3% | |
| 0Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $214k 3,375 shares | -3% | |
| 33Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $3.6M 55,000 shares | -53% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.